• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific warns on battery risk with some older Emblem S-ICDs

Boston Scientific warns on battery risk with some older Emblem S-ICDs

August 27, 2019 By Brad Perriello

Boston Scientific Emblem S-ICDA small group of older Boston Scientific (NYSE:BSX) subcutaneous implantable cardioverter defibrillators have an increased risk of early battery depletion, the company said this month in an advisory letter to physicians.

The Marlborough, Mass.-based company said the issue affects about 400 (0.7%) of its Emblem S-ICD and Emblem MRI S-ICD devices. Those devices have “an elevated likelihood (19% at 3 years) of an electrical component causing accelerated battery depletion,” according to the letter dated August 2019. The affected devices were made in July 2017 and are no longer on the market, Boston said.

“Because this behavior is detectable through regular follow-up care, the projected potential for life-threatening harm in this subset is approximately one in 20,000 at three years. The projected potential for life-threatening harm for all other devices (non-advisory) is approximately one in 5,000,000 at three years,” according to the letter.

The most common outcome is early device replacement; there were no other serious injuries reported, Boston Scientific said, noting that the problem can be detected via an unexpected decrease in battery capacity, or an early elective replacement indicator or end of life battery status. The devices can provide a minimum of 21 days worth of therapy after an elective replacement indication. The cumulative device survival rate at three years for the roughly 56,000 Emblem S-ICDs that have been implanted is 99.6%, the company said.

The company recommended that doctors enroll patients implanted with the affected devices in its Latitude NXT remote monitoring program and run device checks every three months. Device replacement within the 21-day window after ERI was also recommended, along with consideration of prophylactic replacement for higher-risk patients.

“Patient safety remains our highest priority. Although Boston Scientific recognizes the impact of this letter on both you and your patients, we are committed to transparent communication with our physician customers to ensure you have timely, relevant information for managing your patients,” the company said.

Filed Under: Cardiovascular, Featured, Recalls Tagged With: Boston Scientific, Cardiac Rhythm Management

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy